Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)

The study will evaluate M7824 monotherapy versus pembrolizumab as 1L treatment for participants with advanced NSCLC with high PD-L1-tumor expression.
Not Available
II
Iams, Wade
NCT03631706
VICCTHO18139

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: